Streptokinase biosimilar - Biocon

Drug Profile

Streptokinase biosimilar - Biocon

Alternative Names: Myokinase; Recombinant streptokinase - Biocon

Latest Information Update: 14 Oct 2013

Price : $50

At a glance

  • Originator Biocon
  • Class Coenzymes; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Deep vein thrombosis; Myocardial infarction; Pulmonary embolism

Most Recent Events

  • 30 Apr 2008 Launched for Pulmonary embolism in India (IV) before April 2008
  • 30 Apr 2008 Launched for Myocardial infarction in India (IV) before April 2008
  • 30 Apr 2008 Launched for Deep vein thrombosis in India (IV) before April 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top